Trametinib
Trametinib
Trametinib (pronounced tra-MET-in-ib) is a medication used in the treatment of certain types of cancer, including melanoma, non-small cell lung cancer, and thyroid cancer. It is classified as a MEK inhibitor, which means it works by blocking the action of a protein called MEK that is involved in cell growth.
Etymology
The name "Trametinib" is derived from the chemical structure of the drug. The "tra" prefix is short for "trans", referring to the trans configuration of the molecule. The "met" part of the name is an abbreviation for "methyl", a chemical group present in the molecule. The "inib" suffix is common in drug names and indicates that the substance is an inhibitor.
Usage
Trametinib is used in combination with other drugs to treat certain types of cancer. It is usually given after other treatments have failed. The drug is taken orally, usually once a day.
Side Effects
Common side effects of Trametinib include nausea, diarrhea, rash, and fever. More serious side effects can include heart disease, lung disease, and eye problems.
Related Terms
- MEK inhibitor: A type of drug that blocks the action of the MEK protein, which is involved in cell growth.
- Melanoma: A type of skin cancer that begins in the cells that produce the pigment melanin.
- Non-small cell lung cancer: The most common type of lung cancer.
- Thyroid cancer: A type of cancer that begins in the thyroid gland.
External links
- Medical encyclopedia article on Trametinib
- Wikipedia's article - Trametinib
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski